LEAKADINE Trademark

Trademark Overview

On Friday, November 4, 2022, a trademark application was filed for LEAKADINE with the United States Patent and Trademark Office. The USPTO has given the LEAKADINE trademark a serial number of 79361858. The federal status of this trademark filing is REGISTERED as of Tuesday, October 15, 2024. This trademark is owned by TETRA, SIA FIRMA. The LEAKADINE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for treatment of cancer and dermatological diseases and for modulating immune response
leakadine

General Information

Serial Number79361858
Word MarkLEAKADINE
Filing DateFriday, November 4, 2022
Status700 - REGISTERED
Status DateTuesday, October 15, 2024
Registration Number7532445
Registration DateTuesday, October 15, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 30, 2024

Trademark Statements

Goods and ServicesPharmaceutical preparations for treatment of cancer and dermatological diseases and for modulating immune response

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, February 6, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTETRA, SIA FIRMA
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressLV
Party NameTETRA, SIA FIRMA
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressLV
Party NameTETRA, SIA FIRMA
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressLV

Trademark Events

Event DateEvent Description
Friday, February 10, 2023APPLICATION FILING RECEIPT MAILED
Friday, February 3, 2023SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, February 6, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 21, 2023ASSIGNED TO EXAMINER
Monday, August 28, 2023NON-FINAL ACTION WRITTEN
Tuesday, August 29, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, September 19, 2023REFUSAL PROCESSED BY MPU
Tuesday, September 19, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, October 11, 2023REFUSAL PROCESSED BY IB
Thursday, March 21, 2024TEAS PETITION TO REVIVE RECEIVED
Thursday, March 21, 2024PETITION TO REVIVE-GRANTED
Thursday, March 21, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 21, 2024NOTICE OF REVIVAL - E-MAILED
Friday, June 14, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 14, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 10, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 30, 2024PUBLISHED FOR OPPOSITION
Friday, June 14, 2024ASSIGNED TO LIE
Monday, June 24, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 12, 2024NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Monday, July 15, 2024NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, July 30, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Saturday, August 3, 2024NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Tuesday, October 15, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, October 15, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Wednesday, January 15, 2025FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, March 20, 2025FINAL DISPOSITION NOTICE SENT TO IB
Saturday, April 12, 2025FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, March 20, 2025FINAL DISPOSITION PROCESSED

Related Keywords

leakadine modulating immune response diseases dermatological preparations treatment cancer pharmaceutical